Effects of a Novel Selective Peroxisome Proliferator-Activated Receptor α Modulator, Pemafibrate, on Metabolic Parameters: A Retrospective Longitudinal Study

Yanai, Hidekatsu; Katsuyama, Hisayuki; Hakoshima, Mariko

doi:10.3390/biomedicines10020401

Cited by 11 publications

(17 citation statements)

References 59 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We also found serum lipids, such as TG and HDL-C, to be significantly improved when NAFLD patients were treated with pemafibrate. These results are consistent with previous reports ( 14 – 16 ) ( 11 , 17 – 21 ). Notably, the change in liver enzymes was accompanied with a significant improvement in liver stiffness, as measured by SWE.…”

Section: Discussionsupporting

confidence: 94%

“…Additionally, pemafibrate improved liver fibrosis by reducing collagen 1α1 mRNA levels along with a decrease in the levels of pro-inflammatory mRNA ( 12 ). Indeed, pemafibrate induced a significant reduction in alanine aminotransferase (ALT) and γ-glutamyl transpeptidase (γ-GTP) levels in NAFLD patients ( 11 , 14 – 21 ). However, the efficacy of pemafibrate with respect to NAFLD was not addressed in these earlier studies due to cohort size.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Effect of pemafibrate on liver enzymes and shear wave velocity in non-alcoholic fatty liver disease patients

et al. 2023

View full text Add to dashboard Cite

Background/AimsPemafibrate is a selective peroxisome proliferator-activated receptor α modulator that improves serum alanine aminotransferase (ALT) in dyslipidemia patients. Pemafibrate was reported to reduce ALT in non-alcoholic fatty liver disease (NAFLD) patients, but efficacy was not clearly elucidated due to the small size of previous study populations. Therefore, we explored pemafibrate efficacy in NAFLD patients.MethodsWe retrospectively evaluated pemafibrate efficacy on liver enzymes (n = 132) and liver shear wave velocity (SWV, n = 51) in NAFLD patients who had taken pemafibrate for at least 24 weeks.ResultsPatient ALT levels were decreased from 81.0 IU/L at baseline to 48.0 IU/L at week 24 (P < 0.0001). Serum levels of aspartate aminotransferase (AST), γ-glutamyl transpeptidase (γ-GTP) and triglyceride (TG) were significantly decreased, and high-density lipoprotein cholesterol and platelet count were significantly increased, with no change in body weight being observed. Study participant SWV values decreased from 1.45 m/s at baseline to 1.32 m/s at week 48 (P < 0.001). Older age (P = 0.035) and serum TG levels (P = 0.048) were significantly associated with normalized ALT. Changes in AST, ALT, γ-GTP and body weight were significantly correlated with change in SWV.ConclusionPemafibrate significantly improves liver function, serum TG and liver stiffness in NAFLD patients. Pemafibrate is a promising therapeutic agent for NAFLD and may be a candidate for NAFLD patients with elevated TG.

show abstract

Section: Discussionsupporting

confidence: 94%

Section: Introductionmentioning

confidence: 99%

Effect of pemafibrate on liver enzymes and shear wave velocity in non-alcoholic fatty liver disease patients

et al. 2023

View full text Add to dashboard Cite

show abstract

“…Additionally, a significant reduction in TG and non‐HDL‐C and an increase in HDL‐C were observed following pemafibrate treatment. These results are consistent with those of previous reports 33,34 . Recent studies have reported a significant decrease in the FAST score following pemafibrate treatment 16,19,35 and its correlation with the changes in ALT 16 or GGT levels 35 .…”

Section: Discussionsupporting

confidence: 93%

“…These results are consistent with those of previous reports. 33,34 Recent studies have reported a significant decrease in the FAST score following pemafibrate treatment 16,19,35 and its correlation with the changes in ALT 16 or GGT levels. 35 In this study, we found a significant reduction in the MAST score following pemafibrate treatment and a correlation between the reduction of the MAST score and the changes in ALT and GGT levels.…”

Section: Discussionmentioning

confidence: 99%

Evaluation of the effects of pemafibrate on metabolic dysfunction‐associated steatotic liver disease with hypertriglyceridemia using magnetic resonance elastography combined with fibrosis‐4 index and the magnetic resonance imaging‐aspartate aminotransferase score

Ichikawa,

Oba,

Owada

et al. 2023

JGH Open

View full text Add to dashboard Cite

Background and AimIn this retrospective study, we evaluated the effects of pemafibrate treatment in patients with metabolic dysfunction‐associated steatotic liver disease (MASLD) and hypertriglyceridemia using non‐invasive stiffness‐based models, including magnetic resonance elastography (MRE) combined with the fibrosis‐4 (FIB‐4) (MEFIB) index and the magnetic resonance imaging (MRI)‐aspartate aminotransferase (AST) (MAST) score.MethodsIn total, 179 patients with MASLD treated with pemafibrate were enrolled. We evaluated the effects of 48‐week pemafibrate treatment using the MEFIB index, which classifies patients based on the combination of liver stiffness measurement (LSM) on MRE and FIB‐4 and the MAST score, which is calculated based on LSM on MRE, MRI‐proton density fat fraction (MRI‐PDFF), and AST levels.ResultsPemafibrate treatment led to significant reduction in AST, alanine aminotransferase (ALT), and gamma‐glutamyl transferase (GGT) (P = 0.011, <0.001, and <0.001, respectively) and significant improvements in triglyceride and high‐density lipoprotein cholesterol levels (P < 0.001 and <0.001, respectively). The MRI‐PDFF values were not significantly altered. However, a significant decrease in LSM on MRE was detected (P = 0.003). Evaluation of fibrosis using the MEFIB index and MAST score demonstrated significant improvement (P = 0.004 and <0.001, respectively). Changes in the MAST score showed positive correlation with changes in ALT and GGT levels (r = 0.821, P < 0.001, and r = 0.808, P < 0.001, respectively). Additionally, ALT and GGT levels at baseline were significantly associated with improvements in the MAST score (P < 0.001 and <0.001, respectively).ConclusionPemafibrate led to improvements in the MEFIB index and MAST score, as well as liver function. It is a promising therapeutic agent for patients with MASLD and hypertriglyceridemia with the potential to reduce liver‐related events.

show abstract

“…A recent retrospective longitudinal study indicates that pemafibrate significantly reduces plasma TG by 43.8% and increases HDL-C by 10.8% in patients with dyslipidemia after 3 months treatment. Furthermore, this molecule improves liver function and serum levels of uric acid and hemoglobin A1c ( Yanai et al, 2022 ).…”

Section: Strategies For Treatment Of Hypertriglyceridemiamentioning

confidence: 99%

Triglyceride and Triglyceride-Rich Lipoproteins in Atherosclerosis

Zhang

Yin

Qiao

et al. 2022

Front. Mol. Biosci.

View full text Add to dashboard Cite

Cardiovascular disease (CVD) is still the leading cause of death globally, and atherosclerosis is the main pathological basis of CVDs. Low-density lipoprotein cholesterol (LDL-C) is a strong causal factor of atherosclerosis. However, the first-line lipid-lowering drugs, statins, only reduce approximately 30% of the CVD risk. Of note, atherosclerotic CVD (ASCVD) cannot be eliminated in a great number of patients even their LDL-C levels meet the recommended clinical goals. Previously, whether the elevated plasma level of triglyceride is causally associated with ASCVD has been controversial. Recent genetic and epidemiological studies have demonstrated that triglyceride and triglyceride-rich lipoprotein (TGRL) are the main causal risk factors of the residual ASCVD. TGRLs and their metabolites can promote atherosclerosis via modulating inflammation, oxidative stress, and formation of foam cells. In this article, we will make a short review of TG and TGRL metabolism, display evidence of association between TG and ASCVD, summarize the atherogenic factors of TGRLs and their metabolites, and discuss the current findings and advances in TG-lowering therapies. This review provides information useful for the researchers in the field of CVD as well as for pharmacologists and clinicians.

show abstract

Effects of a Novel Selective Peroxisome Proliferator-Activated Receptor α Modulator, Pemafibrate, on Metabolic Parameters: A Retrospective Longitudinal Study

Cited by 11 publications

References 59 publications

Effect of pemafibrate on liver enzymes and shear wave velocity in non-alcoholic fatty liver disease patients

Effect of pemafibrate on liver enzymes and shear wave velocity in non-alcoholic fatty liver disease patients

Evaluation of the effects of pemafibrate on metabolic dysfunction‐associated steatotic liver disease with hypertriglyceridemia using magnetic resonance elastography combined with fibrosis‐4 index and the magnetic resonance imaging‐aspartate aminotransferase score

Triglyceride and Triglyceride-Rich Lipoproteins in Atherosclerosis

Contact Info

Product

Resources

About